Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.


OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by pericles1on Sep 05, 2014 8:23am
109 Views
Post# 22908923

Nice piece of news!

Nice piece of news!
Posted on other site. https://channel.nationalgeographic.com/channel/videos/national-geographic-stands-up-to-cancer/ I have a couple other things to say, while I think AF is truly unethical and not to bright, I am also not happy with Linda. She gave the impression that an analysis of Phase III was in progress. The fact that was not the case was misleading. I'm glad she got the bar lowered to four months but the fact that she did not directly lie is not good enough. Holding tight but I will be more skeptical about her statements in the future.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities